Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125547072 | 12554707 | 2 | F | 20160616 | 20160712 | 20160713 | 20160721 | EXP | PHHY2016FR096208 | SANDOZ | 78.05 | YR | M | Y | 0.00000 | 20160721 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125547072 | 12554707 | 1 | I | TEGRETOL | CARBAMAZEPINE | 1 | Oral | 200 MG, QD | 0 | 200 | MG | TABLET | QD | ||||||
| 125547072 | 12554707 | 2 | I | TEGRETOL | CARBAMAZEPINE | 1 | 0 | TABLET | |||||||||||
| 125547072 | 12554707 | 3 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 15 MG, PRN | 90331 | 15 | MG | ||||||||
| 125547072 | 12554707 | 4 | I | PARKINANE LP | TRIHEXYPHENIDYL HYDROCHLORIDE | 1 | Oral | 5 MG, QD | 0 | 5 | MG | SLOW RELEASE CAPSULES | QD | ||||||
| 125547072 | 12554707 | 5 | I | TERCIAN | CYAMEMAZINE | 1 | Oral | 25 MG, QD | 0 | 25 | MG | FILM-COATED TABLET | QD | ||||||
| 125547072 | 12554707 | 6 | I | TERCIAN | CYAMEMAZINE | 1 | Oral | 50 MG, QD (STRENGTH: 100 MG) | 0 | 50 | MG | FILM-COATED TABLET | QD | ||||||
| 125547072 | 12554707 | 7 | I | HALDOL | HALOPERIDOL | 1 | Oral | 5 MG, BID | 0 | 5 | MG | BID | |||||||
| 125547072 | 12554707 | 8 | C | DIFFU K | POTASSIUM CHLORIDE | 1 | Unknown | 600 MG, QD | Y | 0 | 600 | MG | QD | ||||||
| 125547072 | 12554707 | 9 | C | TERCIAN | CYAMEMAZINE | 1 | Intramuscular | 50 MG/ML, PRN (IF AGITIATION) | U | 0 | |||||||||
| 125547072 | 12554707 | 10 | C | ZOPICLONE | ZOPICLONE | 1 | Unknown | 7.5 MG, PRN | Y | 0 | 7.5 | MG | |||||||
| 125547072 | 12554707 | 11 | C | ZOLPIDEM | ZOLPIDEMOLPIDEM TARTRATE | 1 | Unknown | 10 MG, UNK | Y | 0 | 10 | MG | |||||||
| 125547072 | 12554707 | 12 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | Unknown | 2 DF, QD | U | 0 | 2 | DF | QD | ||||||
| 125547072 | 12554707 | 13 | C | COUMADINE | WARFARIN SODIUM | 1 | Unknown | 4 MG, QD | 44 | MG | U | 0 | 4 | MG | QD | ||||
| 125547072 | 12554707 | 14 | C | COUMADINE | WARFARIN SODIUM | 1 | Unknown | 7 MG, QD | 44 | MG | U | 0 | 7 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125547072 | 12554707 | 1 | Psychotic disorder |
| 125547072 | 12554707 | 2 | Abnormal behaviour |
| 125547072 | 12554707 | 3 | Gastrooesophageal reflux disease |
| 125547072 | 12554707 | 4 | Psychotic disorder |
| 125547072 | 12554707 | 5 | Psychotic disorder |
| 125547072 | 12554707 | 7 | Psychotic disorder |
| 125547072 | 12554707 | 8 | Product used for unknown indication |
| 125547072 | 12554707 | 9 | Product used for unknown indication |
| 125547072 | 12554707 | 10 | Product used for unknown indication |
| 125547072 | 12554707 | 11 | Product used for unknown indication |
| 125547072 | 12554707 | 12 | Phlebitis |
| 125547072 | 12554707 | 13 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125547072 | 12554707 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125547072 | 12554707 | Drug interaction | |
| 125547072 | 12554707 | International normalised ratio decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125547072 | 12554707 | 12 | 20160603 | 0 | ||
| 125547072 | 12554707 | 13 | 20160606 | 20160616 | 0 | |
| 125547072 | 12554707 | 14 | 20160617 | 0 |